BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5-Reference-Cited by-同舟云学术

BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5

Published:2022-12 Issue:12 Volume:22 Page:1663-1665
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Tartof Sara Y,Slezak Jeff M,Puzniak Laura,Hong Vennis,Frankland Timothy B,Ackerson Bradley K,Takhar Harpreet,Ogun Oluwaseye A,Simmons Sarah,Zamparo Joann M,Jodar Luis,McLaughlin John M

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference4 articles.

1. Emergence of SARS-CoV-2 omicron lineages BA.4 and BA.5 in South Africa;Tegally;Nat Med,2022

2. Neutralization of the SARS-CoV-2 omicron BA.4/5 and BA.2.12.1 subvariants;Qu;N Engl J Med,2022

3. SARS-CoV-2 sequences by Variant, Mar 1, 2021,2022

4. BNT162b2 effectiveness and durability against BA.1 and BA.2 hospital and emergency department admissions in a large US health system: a test-negative design;Tartof;SSRN,2022

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BNT162b2 XBB1.5-adapted Vaccine and COVID-19 Hospital Admissions and Ambulatory Visits in US Adults;2023-12-28

2. Modelling the Potential Public Health Impact of Different COVID-19 Vaccination Strategies with an Adapted Vaccine in Singapore;Expert Review of Vaccines;2023-12-12

3. Evaluation of immune response to SARS-CoV-2 Omicron sublineages six months after different vaccination regimens in Italy;Acta Tropica;2023-12

4. A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds;Clinical Infectious Diseases;2023-11-28

5. Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial;The Journal of Infectious Diseases;2023-11-16